ライフサイエンスコーパス: prime-boost

1 es, a resemblance heightened by heterologous prime-boost.

2 ve immunization campaigns or as heterologous prime-boost agents.

3 Here, we show that a prime/boost AIDS vaccine approach elicits potent ADCC ac

4 Heterologous DNA-GP/rAd5-GP prime-boost and single-modality rAd5-GP, as well as the

5 nct immunological advantages over homologous prime-boosts and suggest that the effect of DNA on subse

6 e efficacy of the VSV-SRV serotype 2 vaccine prime-boost approach in RMs.

7 In this report we use a novel prime-boost approach in which the priming injections con

8 unodeficiency virus type 1 infection, that a prime-boost approach with a highly attenuated poxvirus f

9 re detected in SV11 mice ex vivo following a priming-boosting approach and these cells demonstrated h

10 nstructs was evaluated using a "heterologous prime-boost" approach consisting of mucosal priming with

11 of prophylactic efficacy of 52%-58%, whereas prime-boost approaches conferred 38%-47% protection in b

12 that CD8 secondary memory cells, induced by prime-boost approaches, show enhanced protective functio

13 pment of new adenovirus serotypes and better prime-boost approaches, suggesting that many viral vecto

14 e serial immunization steps for heterologous prime-boost-boost can be lengthy, leaving the host vulne

15 Heterologous prime-boost-boost immunization has been shown to result

16 ge, we analyzed splenocytes after priming or prime-boosting by using intracytoplasmic cytokine staini

17 ) T-cell proliferation assays after repeated prime boosting, by measuring the antiviral activity agai

18 c BaL gp120 and BaL SOSIP gp140 protein in a prime-boost combination in guinea pigs to enhance envelo

19 Here, we investigated the optimal prime-boost combination, using DNA, porcine-derived aden

20 This prime/boost combination increased the neutralization of

21 These results suggest that heterologous prime-boost combinations have distinct immunological adv

22 ulosis, BCG and MTBVAC delivered via various prime-boost combinations or alone were compared.

23 We found of all prime-boost combinations tested, an HIV-1 Env peptide su

24 against bovine TB are based on heterologous prime-boost combinations that include BCG, there is a ne

25 diated immune responses induced by different prime-boost combinations where all vectors encode a mult

26 When used in heterologous or in homologous prime-boost combinations, these three vectors generated

27 determine the protection efficacy of various prime-boost combinations, using the same mouse model.

28 ses superior to Ad35-GE-Ad35-GE or rMVA-rMVA prime-boost combinations.

29 eterologous and homologous vector and insert prime-boost combinations.

30 ) or intramuscular (i.m.) route in different prime-boost combinations.

31 1 Gag (rVSVN4CT1gag1) and rMuVgag in various prime-boost combinations.

32 These vaccines were used in cocktails or prime-boost combinations.

33 vaccines were used alone, in cocktails or in prime-boost combinations.

34 These studies used prime/boost combinations of DNA expression plasmids alon

35 Prime/boost combinations of LAIV and TIV in young childr

36 However, testing prime-boost efficiency in long-term protection studies i

37 Heterologous prime-boosting has emerged as a powerful vaccination app

38 , efficacy trial in Thailand reported that a prime-boost human immunodeficiency virus (HIV) vaccine r

39 ara-Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine,

40 onses of similar phenotype are mounted after prime-boost immunization against Plasmodium berghei glid

41 Here, we used a heterologous prime-boost immunization approach using a combination of

42 In this study, using a prime-boost immunization approach, we showed that virus-

43 These findings may inform the design of prime-boost immunization approaches and help improve the

44 Such heterologous prime-boost immunization approaches may provide a basis

45 ortantly, the CD8 memory response from lv-vv prime-boost immunization could effectively prevent autoc

46 AdCh63-MVA heterologous prime-boost immunization induces strong and long-lasting

47 Prime-boost immunization is a promising strategy for ind

48 vestigated both of these possibilities using prime-boost immunization of susceptible mice with a sing

49 A homologous prime-boost immunization protocol with transiently enhan

50 show that a recombinant adenovirus-poxvirus prime-boost immunization regime (known to induce strong

51 ty following an intravenous or intramuscular prime-boost immunization regimen.

52 Prime-boost immunization regimens have proven efficaciou

53 Analysis of different gene-based prime-boost immunization regimens revealed that recombin

54 These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD

55 elicited by these vectors during homologous prime-boost immunization regimens utilizing either high-

56 mpared immune responses induced by different prime-boost immunization regimens with GP and sGP DNA va

57 Thus, prime-boost immunization strategies able to induce mucos

58 Heterologous prime-boost immunization strategies can evoke powerful T

59 Several prime-boost immunization strategies eliciting unmatched

60 Vector prime-boost immunization strategies induce strong cellul

61 We also describe homologous and heterologous prime-boost immunization strategies using novel and prev

62 ere assessed in mice by using a heterologous prime-boost immunization strategy and compared to those

63 trate the robust therapeutic efficacy of the prime-boost immunization strategy with important clinica

64 TCR avidity enhancement may be leveraged by prime-boost immunization to improve GUCY2C-targeted colo

65 Together, these results indicate that prime-boost immunization via NYVAC-KC and either anti-CD

66 d whether the immune response induced by the prime-boost immunization was different from adenoviral v

67 the Th1 and CD8+ T cell responses following prime-boost immunization were seen in both lymphoid and

68 Prime-boost immunization with gene-based vectors has bee

69 Prime-boost immunization with heterologous microbes shar

70 Prime-boost immunization with heterologous vaccines elic

71 Heterologous prime-boost immunization with plasmid DNA and viral vect

72 In addition, prime-boost immunization with the optimized AFP signific

73 fic T cell immunity and protection following prime-boost immunization.

74 y using multiple homologous and heterologous prime/boost immunization regimens in order to optimize t

75 The heterologous prime/boost immunization regimens that involved an initi

76 ng recombinant vectors of the same family in prime/boost immunization strategies to optimize vaccine-

77 A prime/boost immunization strategy was employed using gp1

78 lly, we demonstrated that mice that received prime-boost immunizations of LT-antigen proteins were mo

79 In this study, we utilized two regimens of prime-boost immunizations with AdC serotype SAd-V23 (als

80 The T-cell response was altered by different prime-boost immunizations, with the optimal CD8 immunity

81 A*01+ monkeys that had received heterologous prime/boost immunizations prior to challenge maintained

82 ibility has arisen of employing heterologous prime/boost immunizations using diverse members of the s

83 opeptide (Lipo/Lipo) vaccine, the Lipo/rAdv5 prime/boost immunized mice 1) developed potent and susta

84 on from the throats of 2 of 6 animals in the prime-boost Imvamune group, whereas there was no confirm

85 immunization of Acam2000 (132 U/ml) and the prime-boost Imvamune regime (69 U/ml) prior to challenge

86 rough either vaccination directly or through prime/boost in the prior influenza season.

87 -specific IgG1 responses, after subcutaneous prime/boosts in mice, were similar when PNSN(OVA + CpG)

88 te that vaccination with heterologous insert prime boosting increased T-cell responses to shared epit

89 o shared epitopes, while heterologous vector prime boosting increased the number of T-cell epitopes r

90 e, from subjects enrolled in an H5N1 DNA/MIV-prime-boost influenza vaccine trial, we sorted hemagglut

91 This study defines the shortest prime-boost interval associated with an improved respons

92 the 60 participants and evaluated a reduced prime-boost interval in another 16 participants.

93 tibody responses after an MIV boost when the prime-boost interval is 12-24 weeks.

94 55%-70% of recipients with an H5 DNA and MIV prime-boost interval of </=8 weeks (GMT, 51-70) and 44%

95 8 weeks (GMT, 51-70) and 44% with an MIV-MIV prime-boost interval of 24 weeks (GMT, 27).

96 ompared responses to that of 2 doses of MIV (prime-boost interval, 24 weeks).

97 A prime-boost intranasal vaccination strategy using TBI in

98 are not yet clear, the heterologous VSV/SFVG prime-boost is clearly a potent vaccine regimen for indu

99 Recent clinical trials of new heterologous prime-boost malaria vaccine regimens using DNA, fowlpox

100 Heterologous prime-boost may provide a more effective vaccination str

101 compared with mice immunized once with LVS, primed-boosted mice had a higher survival rate (75% vers

102 l particles encoding HCV proteins in various prime/boost modalities in BALB/c mice.

103 This prime-boost modality generated similar serum and mucosal

104 unization or in a homologous or heterologous prime-boost modality.

105 l lipopeptide/adenovirus type 5 (Lipo/rAdv5) prime/boost mucosal vaccine for induction of CD8(+) T ce

106 y, we compared the effectiveness of a single prime-boost protocol consisting of VSV vectors expressin

107 We explored a novel prime-boost protocol that used two live mucosal agents t

108 The effect was less consistent when this prime-boost protocol was reversed.

109 CP250) or Gag, Pol, and gp160 (vCP1420) in a prime-boost protocol with their homologous vaccine nativ

110 vaccination strategies based on heterologous prime-boost protocols using Mycobacterium bovis bacillus

111 of age, the administration of a diversified prime/boost recombinant CEA-poxvirus-based vaccine regim

112 Intravaginal HPV prime/boost reduced cervicovaginal viral titers 1,000-fo

113 Ad63-MVA AMA1 administered in a heterologous prime-boost regime was shown to be safe and immunogenic,

114 virus- and vaccinia virus-based vectors in a prime-boost regime.

115 d5 boosting (n = 50) or a homologous Ad5/Ad5 prime-boost regimen (n = 70).

116 or a heterologous DNA-gag/Ad5-gag (DNA/Ad5) prime-boost regimen and challenged them with a high dose

117 potential of an accelerated heterologous rAd prime-boost regimen as a candidate HIV-1 vaccine for new

118 A prime-boost regimen consisting of mucosal delivery of Pf

119 nate rhesus macaques with a new heterologous prime-boost regimen designed to optimize induction of an

120 ve recently reported that a heterologous rAd prime-boost regimen expressing simian immunodeficiency v

121 These vectors, when used in a heterologous prime-boost regimen in BALB/c mice, are capable of induc

122 unizing with the resultant combinations in a prime-boost regimen induced both cellular and humoral im

123 Immunizations with a single variant in a prime-boost regimen induced no or low cross-reactivity t

124 In contrast, an accelerated heterologous prime-boost regimen involving administration of rAd35 at

125 gen-nucleic acid complexes [LANACs]) using a prime-boost regimen provided 100% protection in mice cha

126 ine will likely be based upon a heterologous prime-boost regimen that induces both appropriate T-cell

127 The superior systemic prime-boost regimen was then compared to a mucosal-boost

128 Here we show that a homologous prime-boost regimen with a mixture of MVA (Modified Vacc

129 -vector immunity, compared with a homologous prime-boost regimen with either vector alone.

130 roteoliposomes were administered alone or in prime-boost regimen with trimeric envelope gp140(CA018)

131 In this study we compared a prime-boost regimen with two serologically distinct repl

132 c y179) immunization after priming with DNA (prime-boost regimen) increased antibody titers to the ho

133 ost vaccination was equivalent to a systemic prime-boost regimen, but the mucosally applied modality

134 mpared to those observed following a DNA/Ad5 prime-boost regimen, likely reflecting differences in an

135 raised using a heterologous DNA-viral vector prime-boost regimen, resulting in a high proportion of c

136 coding HCV NS proteins in a dose escalation, prime-boost regimen, with and without concomitant pegyla

137 Ankara (MVA) and used to immunize mice in a prime-boost regimen.

138 se progression in monkeys immunized with the prime-boost regimen.

139 ogenicity early in life using a heterologous prime-boost regimen.

140 elope (Env) gene inserts (clade A or B) in a prime-boost regimen.

141 simian adenovirus and were administered in a prime-boost regimen.

142 The homologous ID93/GLA-SE prime/boost regimen also induced long-lived protection.

143 a low avidity for the target epitope, but a prime/boost regimen can expand higher avidity clones in

144 ave previously demonstrated induction by the prime/boost regimen of mucosal antibodies that inhibit t

145 The prime/boost regimen provided significantly better protec

146 In addition, this prime/boost regimen resulted in the induction of anti-E1

147 xplore the use of divergent pox vectors in a prime/boost regimen to elicit high-frequency cellular im

148 poxviruses expressing PSA and delivered in a prime/boost regimen was feasible and associated with min

149 mice intranasally immunized with CLH001 in a prime/boost regimen were fully protected against lethal

150 ion with A244 V1/V2 fragments alone, or in a prime/boost regimen with gp120, enhanced the antibody re

151 n this study, we show that such heterologous prime boost regimens based on E1-deleted adenoviral vect

152 us-specific T-cell responses in heterologous prime boost regimens.

153 ts have important implications for design of prime-boost regimens against tuberculosis in humans.

154 that multiepitope plasmid DNA vaccine-based prime-boost regimens can efficiently prime for CTL respo

155 Prime-boost regimens comparing different combinations of

156 c CD8(+) T cells induced by various prime or prime-boost regimens correlated with antitumor efficacy,

157 tomic separation strategies and heterologous prime-boost regimens generated codominant responses agai

158 Interestingly, prime-boost regimens have demonstrated longer protection

159 Since prime-boost regimens have the potential to achieve long-

160 ports the rationale for testing heterologous prime-boost regimens in humans.

161 highlight the challenges of optimization of prime-boost regimens in mice where BCG drives persistent

162 against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular an

163 e data suggest that optimal heterologous rAd prime-boost regimens should include two vectors that are

164 hlight the ability of optimized viral vector prime-boost regimens to generate more protective and sus

165 ing specific rAd vectors alone or as part of prime-boost regimens to induce CD8(+) T cells for rapid

166 Prime-boost regimens using independent vaccine platforms

167 Here, we report that prime-boost regimens using modified vaccinia virus Ankar

168 stered recombinant adenoviruses were used in prime-boost regimens with adjuvanted proteins or recombi

169 In the current study, we examined different prime-boost regimens with F1-V and demonstrate that (i)

170 e approach showing efficacy when combined in prime-boost regimens with recombinant protein or viral v

171 ned in liver, blood, and spleen after Ad/MVA prime-boost regimens, and animals were protected against

172 The present study investigated two prime-boost regimens, both starting vaccination with sin

173 he safety and immunogenicity of heterologous prime-boost regimens, with a New York vaccinia HIV clade

174 cell responses, we assessed rAds as part of prime-boost regimens.

175 ectors than with Ad5 vectors in heterologous prime-boost regimens.

176 the heterologous compared to the homologous prime-boost regimens.

177 rt-focus responses using heterologous vector prime-boost regimens.

178 inistered with rVSVN4CT1gag1 in heterologous prime-boost regimens.

179 ning the overall potency of heterologous rAd prime-boost regimens.

180 te the development of novel heterologous rAd prime-boost regimens.

181 essed the immunogenicity of heterologous rAd prime-boost regimens.

182 Ls can, however, be expanded by heterologous prime-boost regimens.

183 t have been an effective priming modality in prime-boost regimens.

184 -lymphocyte responses have been heterologous prime/boost regimens employing a plasmid DNA prime and a

185 We found that both prime/boost regimens significantly enhance cellular and

186 Heterologous "prime-boost" regimens that involve priming with plasmid

187 However, prime boost regimes involving two heterologous viral vec

188 ombinant fowlpox virus, FP9, vaccine in such prime-boost regimes can elicit complete sterile protecti

189 DNA and modified vaccinia virus Ankara (MVA) prime-boost regimes were assessed by using either thromb

190 The prime/boost schedule was well tolerated with few adverse

191 AIV, or combinations of LAIV and TIV in both prime/boost sequences.

192 ncy virus (HIV) vaccine approaches emphasize prime boost strategies comprising multiple doses of DNA

193 several papers have highlighted the power of prime-boost strategies in eliciting protective cellular

194 et, the mechanisms underlying the synergy of prime-boost strategies remain incompletely defined.

195 responses with these features are induced by prime-boost strategies, using heterologous vectors, hete

196 ngage secondary CD8(+) T-cell activation for prime-boost strategies.

197 icial for immunization studies using various prime-boost strategies.

198 tant implications for vaccinations involving prime-boost strategies.

199 outes of administration, vector designs, and prime-boost strategies.

200 cal trials testing vector-based heterologous prime-boost strategies.

201 g the use of model antigens and plasmids for prime-boost strategies.

202 ation strategies, particularly "heterologous prime-boost" strategies against tumors, and provide evid

203 rats were intramuscularly vaccinated using a prime boost strategy with gD/AS04 (Simplirix vaccine) or

204 vaccinia-gag challenge, suggesting that this prime-boost strategy can induce strong cellular immunity

205 ng followed by an rMVA boost was the optimal prime-boost strategy for male mice as determined by the

206 mice, providing a strong evidence that lv-vv prime-boost strategy is an effective approach for cancer

207 smitted/founder (T/F) HIV Env immunogen in a prime-boost strategy modeled after the moderately protec

208 vaccinia virus-induced mortality; however, a prime-boost strategy reduced the severity of the vaccini

209 Rv CNS infection afforded by BCG/Mtb72F in a prime-boost strategy was similar to that by BCG alone.

210 When Ad5-ID93 is administered in a prime-boost strategy with ID93/GLA-SE, both CD4(+) and C

211 l immunization followed by oral vaccination (prime-boost strategy).

212 lowing the second Ag dose is integral to the prime-boost strategy, it remains unclear when, after pri

213 This combination prime-boost strategy, utilizing replication competent ad

214 One particularly promising approach is the prime-boost strategy, which has been shown to generate h

215 s to be used early in life in a heterologous prime-boost strategy.

216 eoplasia were vaccinated with a heterologous prime/boost strategy consisting of gene gun-delivered PS

217 Using a prime/boost strategy, high doses of GP/VSVDeltaG partial

218 live attenuated MV vaccine in a heterologous prime-boost to protect against measles early in life.

219 1497 participants in canarypox HIV-1 vaccine prime-boost trials, 28 (1.9%) acquired HIV-1 infection a

220 Heterologous prime boost vaccination minimizes contraction of anamnes

221 This study exploited heterologous prime boost vaccination to discover parameters regulatin

222 Thus, complementary prime boost vaccination, in which prime and boost favor

223 d to i) assess the therapeutic efficacy of a prime-boost vaccination and ii) investigate the mechanis

224 CD4 immune response is increased by DNA/ADV prime-boost vaccination and that these components work s

225 The results support a prime-boost vaccination approach in young children for p

226 achieve such long term immune responses is a prime-boost vaccination approach using a DNA priming ino

227 VA), and attenuated fowlpox strain, FP9, for prime-boost vaccination approaches against Plasmodium fa

228 ort further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis.

229 Heterologous prime-boost vaccination has been shown to be an efficien

230 Only heterologous prime-boost vaccination induced modest cross-reactive HI

231 have shown that amplifying T-cell numbers by prime-boost vaccination is most effective with a substan

232 otential logistic advantages for large-scale prime-boost vaccination of human populations.

233 Repetitive antigen stimulation by prime-boost vaccination or pathogen reencounter increase

234 cines should be considered a potent prime in prime-boost vaccination protocols.

235 Sheep received a prime-boost vaccination regime comprising intramuscular

236 Here we show that a heterologous prime-boost vaccination regime of DNA either intramuscul

237 ine monoclonal antibodies (MAbs) utilizing a prime-boost vaccination regimen with a Zaire ebolavirus

238 These results suggest that heterologous prime-boost vaccination regimens enhance immunity by inc

239 Prime-boost vaccination regimes involving plasmid DNA an

240 Heterologous prime-boost vaccination results in increased frequencies

241 tered subcutaneously to BALB/c mice, using a prime-boost vaccination schedule.

242 Prime-boost vaccination strategies against HIV-1 often i

243 led to the history of Ag experience and that prime-boost vaccination strategies have important conseq

244 ar whether inclusion of multiple variants in prime-boost vaccination strategies improves recognition

245 g multiple variants for a given immunogen in prime-boost vaccination strategies is one approach that

246 We show that prime-boost vaccination strategies provide protection ag

247 results may have important implications for prime-boost vaccination strategies.

248 In this study, we employed a heterologous prime-boost vaccination strategy comprising intradermall

249 Thus, the LVS DeltacapB-rLm/iglC prime-boost vaccination strategy holds substantial promi

250 Our data shows that a prime-boost vaccination strategy was effective in eradic

251 mice vaccinated with live P. murina using a prime-boost vaccination strategy were protected from a s

252 study reports the efficacy of a heterologous prime-boost vaccination using DNA and vaccinia viruses (

253 Prime-boost vaccination via sequential s.c. and i.m. adm

254 In this study, we show that prime-boost vaccination with a mismatched SIV envelope (

255 Prime-boost vaccination with DNA and MVA encoding ME-TRA

256 These data demonstrate that prime-boost vaccination with recombinant DNA and MVA vec

257 These results demonstrate that prime-boost vaccination with SIV Gag protein/poly-IC imp

258 therapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosi

259 Conversely, prime/boost vaccination proved to be of no advantage or

260 Alternate prime/boost vaccination regimens employing recombinant r

261 munogens might be used as priming vectors in prime/boost vaccination regimens for the induction of ce

262 Both single-dose and prime/boost vaccination regimens protected mice against

263 We explored the concept of heterologous prime/boost vaccination using 2 therapeutic vaccines cur

264 In this article, we demonstrate that prime/boost vaccination with D27-pLpxL confers better pr

265 the basis of preclinical synergy, we tested prime/boost vaccination with GVAX and CRS-207 in pancrea

266 eracts the improved survival associated with prime/boost vaccination without significantly impacting

267 mmunity and high levels of protection of the priming-boosting vaccination against both systemic and m

268 ection using plasmid DNA in a prime, but not prime-boost, vaccination regimen.

269 In mice, DC/CoAT prime-boost vaccinations targeting either MHC class I or

270 BALB/c mice were immunized with a prime-boost vaccine and exposed to a lethal intranasal d

271 Importance: The Thai RV144 ALVAC/AIDSVax prime-boost vaccine efficacy trial represents the only e

272 Similar responses were observed after a prime-boost vaccine regimen in three female hematopoieti

273 The heterologous prime-boost vaccine regimen used recombinant DNA for pri

274 combination of vectors for heterologous rAd prime-boost vaccine regimens and the extent of cross-rea

275 Heterologous prime-boost vaccine regimens induced particularly high-f

276 The development of optimal prime-boost vaccine regimens is a high priority for the

277 We characterized prime-boost vaccine regimens using heterologous and homo

278 Our results demonstrate that heterologous prime-boost vaccine regimens with alternative-serotype A

279 s and can be combined as potent heterologous prime-boost vaccine regimens.

280 fluences the protective efficacy afforded by prime-boost vaccine regimens.

281 f these recent developments on the future of prime-boost vaccine strategies.

282 ng the quality of the B cell response to new prime-boost vaccine strategies.

283 ChAd63-MVA is a promising heterologous prime-boost vaccine strategy that could be applied to nu

284 CD8(+) T cell responses with a heterologous prime/boost vaccine approach could induce long-lived vac

285 ting of the vaginal mucosa with a Lipo/rAdv5 prime/boost vaccine elicits a potent, MyD88-dependent, a

286 ic immunity and T-cell memory generated by a prime/boost vaccine regimen delivered by either successi

287 aluate the feasibility and tolerability of a prime/boost vaccine strategy using vaccinia virus and fo

288 The Thai HIV phase III prime/boost vaccine trial (RV144) using ALVAC-HIV (vCP15

289 We evaluated four priming-boosting vaccine regimens for the highly pathoge

290 for rapid expansion of CD8(+) T cells using prime-boost vaccines by targeting privileged sites for A

291 Three prime-boost vector combinations encoding HIV Env stimula

292 MVATG16643 vaccination (from 3% to 25%), and prime/boost was the only regimen that activated quadrifu

293 IV Gag p24 and Gag p24 protein and show that prime boost with protein and adjuvant followed by NYVAC

294 owing secondary challenge suggested that the prime-boost with the -NP-PA viruses gave a response over

295 Prime-boost with the viral vector vaccines, FP9 followed

296 Heterologous prime-boost with the viral vectors simian adenovirus 63

297 In contrast, intramuscular prime/boost with an adenovirus type 5 vector induced a h

298 Heterologous prime/boost with Cy/GVAX and CRS-207 extended survival f

299 An HPV intravaginal prime/boost with different HPV serotypes induced 10-fold

300 agnitude than those elicited by a homologous prime/boost with rMVA.